Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus

Trial Profile

Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs TF 6450 (Primary) ; Faldaprevir; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Trek Therapeutics
  • Most Recent Events

    • 13 Feb 2017 Results published in a Trek Therapeutics media release.
    • 13 Feb 2017 Results from this trial will be presented at the Asian Pacific Association for the Study of the Liver (APASL) conference, according to a Trek Therapeutics media release.
    • 27 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top